UBX-382

UBX-382 is an orally active BTK PROTAC degrader with a DC50 of 4.56 nM. UBX-382 inhibits B-cell receptor signaling by targeting BTK. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins. UBX-382 inhibits tumor growth in murine xenograft models harboring wild-type or C481S mutant BTK-expressing TMD-8 cells. UBX-382 can be used for the study of B-cell-related blood cancers[1].

Product Specifications

CAS Number

[2884554-45-2]

UNSPSC

12352005

Target

Btk; ERK; MEK; PROTACs; Syk

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; PROTAC; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ubx-382.html

Purity

96.20

Solubility

10 mM in DMSO

Smiles

O=C1C2=CC=C(N3CCC(CC3)CN4CC5=CC(NC6=NC7=C(C(NC8=C(C)C=CC=C8C)=NN7C)C=N6)=CC=C5CC4)C=C2C(N1C9C(NC(CC9)=O)=O)=O

Molecular Formula

C42H44N10O4

Molecular Weight

752.86

References & Citations

[1]Lim YS, et al. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models. Blood Adv. 2023;7 (1) :92-105.